Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Ryma Santiago

Nurse Practitioner Gurnee, IL Nurse Practitioner

NPI 1245814128 CMS profile 10692109

20 Tower Ct Ste C, Gurnee, IL 60031

Open in the dashboard

General payments

$33,198

993 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ryma Santiago of Gurnee, IL is reported in the CMS Open Payments database as having received $33,198 across 993 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,311 239
2024 General $13,165 317
2023 General $8,907 259
2022 General $3,199 160
2021 General $617 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ryma Santiago
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Ryma Santiago were reported at $7,311. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Ryma Santiago Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $617 $135 $40–$426 $132
2022 $3,199 $152 $48–$470 $149
2023 $8,907 $166 $54–$529 $160
2024 $13,165 $173 $55–$556 $164
2025 $7,311 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $16,905 90 payments
  2. Janssen Biotech, Inc. $4,942 297 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $2,665 143 payments
  4. AbbVie, Inc. $1,632 102 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,577 92 payments
  6. Pfizer Inc. $938 60 payments
  7. Ardelyx, Inc. $926 49 payments
  8. Celgene Corporation $678 38 payments
  9. Ironwood Pharmaceuticals, Inc $479 30 payments
  10. Phathom Pharmaceuticals, Inc. $369 24 payments
  11. Other $2,087 68 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $17,358 954 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13,500 11 payments
  3. Travel and Lodging $2,006 22 payments
  4. Education $334 6 payments
Products named General payments · program years 2021–2025
  1. OMVOH $10,937 54 payments
  2. STELARA $3,534 193 payments
  3. ENTYVIO $1,789 93 payments
  4. TREMFYA $1,760 107 payments
  5. XIFAXAN $1,450 82 payments
  6. IBSRELA $926 49 payments
  7. VELSIPITY $912 59 payments
  8. ZEPOSIA $816 38 payments
  9. XELJANZ $804 52 payments
  10. CREON $574 31 payments
  11. Other $5,129 302 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

312

Median for Nurse Practitioner: 389

Drug cost

$81,616

Median for Nurse Practitioner: $21,885

Branded share of claims

21.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 43 $47,769
Ibsrela Tenapanor Hcl Brand 11 $28,955
Pantoprazole Sodium Generic 106 $1,618
Omeprazole Generic 82 $1,455
Colestipol Hcl Generic 19 $818
Famotidine Generic 24 $408
Esomeprazole Magnesium Generic 13 $356
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 14 $238

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$42,986

Medicare's payments for the services billed

Medicare patients

287

Average age 75

Services billed

527

186 women, 101 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Diabetes 44%
Ischemic heart disease 39%
Chronic kidney disease 39%
Heart failure 33%
Depression 33%
Atrial fibrillation 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OMVOH
$7,823 — —
STELARA
$1,002 — —
TREMFYA
$481 — —
ENTYVIO
$313 — —
LINZESS
$303 43 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

993 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record